8-K: Alkermes Announces Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia

Alkermes plc reported positive topline results from its Phase 3 REVITALYZ study, showing LUMRYZ significantly improved symptoms of idiopathic hypersomnia.

Summary

• Alkermes plc announced positive topline results from the REVITALYZ Phase 3 study evaluating LUMRYZ (sodium oxybate) extended-release oral suspension for idiopathic hypersomnia (IH).
• The study met its primary endpoint, demonstrating statistically significant improvements in excessive daytime sleepiness (ESS) compared to placebo (p<0.0001).
• Key secondary endpoints, including Patient Global Impression of Change (PGI-C) and Idiopathic Hypersomnia Severity Scale (IHSS), also showed statistically significant improvements for LUMRYZ.
• The safety profile of LUMRYZ in the study was consistent with its known safety profile, with common adverse events including nausea, headache, anxiety, dizziness, and vomiting.
• Alkermes plans to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026.
• A settlement and license agreement restricts Alkermes from marketing LUMRYZ for IH before March 1, 2028.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with strong clinical results and a clear path towards regulatory submission, although market access is delayed.

Positives

• LUMRYZ met all primary and key secondary endpoints in the REVITALYZ Phase 3 study.
• Demonstrated statistically significant and clinically meaningful improvements in excessive daytime sleepiness and patient-reported disease severity.
• The safety profile was consistent with previously observed data for LUMRYZ, with no new safety signals identified.
• The results support the potential utility of once-nightly LUMRYZ as an effective treatment for IH.

Negatives

• A settlement and license agreement prevents marketing LUMRYZ for IH before March 1, 2028, even if approved earlier.
• The most common treatment-emergent adverse events included nausea, headache, anxiety, dizziness, and vomiting.

Risks

• The FDA may not agree with Alkermes' regulatory approval strategies for the sNDA.
• Clinical results may not be predictive of future clinical results or real-world outcomes.
• LUMRYZ could be shown to be ineffective or unsafe.
• Risks and uncertainties described in Alkermes' Form 10-K for the year ended December 31, 2025, and subsequent filings.

Future Outlook

Alkermes plans to file a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) by the end of 2026, based on the positive results of the REVITALYZ Phase 3 study.

Management Comments

• "The data from REVITALYZ demonstrate the potential utility of once-nightly LUMRYZ as an effective treatment for excessive daytime sleepiness associated with IH, building upon its established therapeutic value in narcolepsy."
• "This is a community with limited approved therapeutic options. These findings constitute an important contribution to the clinical understanding of treatment approaches for patients with IH, for whom disruptive symptoms present particular treatment challenges."
• "We look forward to advancing LUMRYZ as a potential treatment for adults with idiopathic hypersomnia based on the clear and compelling outcome of the REVITALYZ study."
• "Historically, people living with sleep disorders have had limited treatment options from which to choose, and Alkermes is motivated to contribute to the overall clinical landscape of sleep medicine through research such as this."

Industry Context

StockSavvy.ai notes that the positive results for LUMRYZ in idiopathic hypersomnia could expand Alkermes' presence in the sleep disorder market, addressing a significant unmet need for patients with limited treatment options.

Stakeholder Impact

• Shareholders may see increased value if LUMRYZ is approved for IH and commercialized successfully.
• Patients with idiopathic hypersomnia may gain access to a new treatment option.
• Healthcare providers will have a new therapeutic option to consider for IH patients.

Next Steps

• Present detailed results from REVITALYZ at an upcoming medical meeting.
• File a supplemental New Drug Application (sNDA) with the U.S. FDA by the end of 2026.
• Continue to develop pipeline candidates for other neurological disorders.

Key Dates

Recommendation

The positive clinical data is a significant step, but the restriction on marketing LUMRYZ for IH until March 1, 2028, introduces a substantial delay that tempers immediate enthusiasm. Investors should hold to see the FDA's review process and the company's strategy to navigate the post-2028 market entry.

Keywords

Idiopathic Hypersomnia, LUMRYZ, Alkermes, Phase 3 Study, Excessive Daytime Sleepiness, Neurological Sleep Disorder, Sodium Oxybate, REVITALYZ